var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/service/mendeley/941c2fd4-a583-308f-aea6-f6aaaa4aba4e/group/11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5?jsonp=1&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/service/mendeley/941c2fd4-a583-308f-aea6-f6aaaa4aba4e/group/11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5?jsonp=1&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/service/mendeley/941c2fd4-a583-308f-aea6-f6aaaa4aba4e/group/11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5?jsonp=1&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
    2. \n
  2. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
    3. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2019\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus.\n \n \n \n \n\n\n \n Benhalima, K.; Minschart, C.; Van Crombrugge, P.; Calewaert, P.; Verhaeghe, J.; Vandamme, S.; Theetaert, K.; Devlieger, R.; Pierssens, L.; Ryckeghem, H.; Dufraimont, E.; Vercammen, C.; Debie, A.; De Block, C.; Vandenberghe, G.; Van Imschoot, S.; Verstraete, S.; Buyse, L.; Wens, J.; Muyldermans, J.; Meskal, A.; De Spiegeleer, S.; and Mathieu, C.\n\n\n \n\n\n\n Acta Clinica Belgica, 00(00): 1-8. 7 2019.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n \n \"TheWebsite\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{\n title = {The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus},\n type = {article},\n year = {2019},\n keywords = {Gestational diabetes mellitus,consensus,pregnancy,screening,type 2 diabetes},\n pages = {1-8},\n volume = {00},\n websites = {https://doi.org/10.1080/17843286.2019.1637389,https://www.tandfonline.com/doi/full/10.1080/17843286.2019.1637389},\n month = {7},\n publisher = {Taylor & Francis},\n id = {9f0c396a-594f-350d-8efb-94ef8a77aaf2},\n created = {2019-09-05T15:10:11.008Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2019-09-05T15:10:19.619Z},\n read = {true},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n private_publication = {false},\n bibtype = {article},\n author = {Benhalima, Katrien and Minschart, Caro and Van Crombrugge, Paul and Calewaert, Peggy and Verhaeghe, Johan and Vandamme, Siska and Theetaert, Katrien and Devlieger, Roland and Pierssens, Leen and Ryckeghem, Hannah and Dufraimont, Els and Vercammen, Chris and Debie, Ann and De Block, Christophe and Vandenberghe, Griet and Van Imschoot, Sylva and Verstraete, Sabine and Buyse, Luk and Wens, Johan and Muyldermans, Joke and Meskal, Anissa and De Spiegeleer, Sandy and Mathieu, Chantal},\n doi = {10.1080/17843286.2019.1637389},\n journal = {Acta Clinica Belgica},\n number = {00}\n}
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2016\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Order of blood draw: Opinion Paper by the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE).\n \n \n \n \n\n\n \n Cornes, M.; van Dongen-Lases, E.; Grankvist, K.; Ibarz, M.; Kristensen, G.; Lippi, G.; Nybo, M.; Simundic, A.; and on behalf of the Working Group for\n\n\n \n\n\n\n Clinical Chemistry and Laboratory Medicine (CCLM), 0(0): 27-31. 2016.\n \n\n\n\n
\n\n\n\n \n \n \"OrderPaper\n  \n \n \n \"OrderWebsite\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{\n title = {Order of blood draw: Opinion Paper by the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)},\n type = {article},\n year = {2016},\n keywords = {analytical phase,clinical chemistry,corresponding author,department,michael cornes,order of draw,patient safety,phlebotomy,pre-,preanalytical quality,royal wolverhampton nhs trust,wolverhampton},\n pages = {27-31},\n volume = {0},\n websites = {http://www.degruyter.com/view/j/cclm.ahead-of-print/cclm-2016-0426/cclm-2016-0426.xml},\n id = {22f2c4e3-9451-36ae-810c-d30169f873c7},\n created = {2016-11-21T15:43:08.000Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {true},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n private_publication = {false},\n bibtype = {article},\n author = {Cornes, Michael and van Dongen-Lases, Edmée and Grankvist, Kjell and Ibarz, Mercedes and Kristensen, Gunn and Lippi, Giuseppe and Nybo, Mads and Simundic, Ana-Maria and on behalf of the Working Group for, undefined},\n doi = {10.1515/cclm-2016-0426},\n journal = {Clinical Chemistry and Laboratory Medicine (CCLM)},\n number = {0}\n}
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2015\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.\n \n \n \n \n\n\n \n Wiegman, A.; Gidding, S., S.; Watts, G., F.; Chapman, M., J.; Ginsberg, H., N.; Cuchel, M.; Ose, L.; Averna, M.; Boileau, C.; Borén, J.; Bruckert, E.; Catapano, A., L.; Defesche, J., C.; Descamps, O., S.; Hegele, R., A.; Hovingh, G., K.; Humphries, S., E.; Kovanen, P., T.; Kuivenhoven, J., A.; Masana, L.; Nordestgaard, B., G.; Pajukanta, P.; Parhofer, K., G.; Raal, F., J.; Ray, K., K.; Santos, R., D.; Stalenhoef, A., F.; Steinhagen- Thiessen, E.; Stroes, E., S.; Taskinen, M.; Tybjærg-Hansen, A.; and Wiklund, O.\n\n\n \n\n\n\n European Heart Journal, 36(36): 2425-2437. 9 2015.\n \n\n\n\n
\n\n\n\n \n \n \"FamilialPaper\n  \n \n \n \"FamilialWebsite\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n\n\n\n
\n 
@article{\n title = {Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment},\n type = {article},\n year = {2015},\n keywords = {Hypercholesterolemie},\n pages = {2425-2437},\n volume = {36},\n websites = {http://eurheartj.oxfordjournals.org/lookup/doi/10.1093/eurheartj/ehv157},\n month = {9},\n day = {21},\n id = {54550968-724b-3697-a36f-17d0ac446c0f},\n created = {2015-11-10T11:55:28.000Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n private_publication = {false},\n bibtype = {article},\n author = {Wiegman, Albert and Gidding, Samuel S. and Watts, Gerald F. and Chapman, M. John and Ginsberg, Henry N. and Cuchel, Marina and Ose, Leiv and Averna, Maurizio and Boileau, Catherine and Borén, Jan and Bruckert, Eric and Catapano, Alberico L. and Defesche, Joep C. and Descamps, Olivier S. and Hegele, Robert A. and Hovingh, G. Kees and Humphries, Steve E. and Kovanen, Petri T. and Kuivenhoven, Jan Albert and Masana, Luis and Nordestgaard, Børge G. and Pajukanta, Päivi and Parhofer, Klaus G. and Raal, Frederick J. and Ray, Kausik K. and Santos, Raul D. and Stalenhoef, Anton F.H. and Steinhagen- Thiessen, Elisabeth and Stroes, Erik S. and Taskinen, Marja-Riitta and Tybjærg-Hansen, Anne and Wiklund, Olov},\n doi = {10.1093/eurheartj/ehv157},\n journal = {European Heart Journal},\n number = {36}\n}
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2013\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Third Universal Definition of Myocardial Infarction.\n \n \n \n \n\n\n \n Jaffe, A., S.\n\n\n \n\n\n\n Clinical Biochemistry, 46(1-2): 1-4. 2013.\n \n\n\n\n
\n\n\n\n \n \n \"ThirdPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{\n title = {Third Universal Definition of Myocardial Infarction},\n type = {article},\n year = {2013},\n pages = {1-4},\n volume = {46},\n id = {8483fc8a-2509-3e89-ae8a-d0a40721bf5e},\n created = {2015-08-07T15:11:39.000Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n private_publication = {false},\n abstract = {Given the considerable advances in recent years in myocardial infarction diagnosis and management, the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA), together with the World Heart Federation WHF recently published an expert consensus document to establish a universal definition for myocardial infarction. The consensus document recognizes five separate myocardial infarction categories based on the differences in pathophysiology, and whether percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery is involved. The new consensus document expands the criteria for defining myocardial infarction by adding new ECG criteria and imaging modalities, and also includes patients who present with sudden death. The Israel Heart Society has adopted the new universal definition and recommends its use by clinicians, researchers and epidemiologists. .},\n bibtype = {article},\n author = {Jaffe, Allan S.},\n doi = {10.1016/j.clinbiochem.2012.10.036},\n journal = {Clinical Biochemistry},\n number = {1-2}\n}
\n
\n\n\n
\n Given the considerable advances in recent years in myocardial infarction diagnosis and management, the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA), together with the World Heart Federation WHF recently published an expert consensus document to establish a universal definition for myocardial infarction. The consensus document recognizes five separate myocardial infarction categories based on the differences in pathophysiology, and whether percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery is involved. The new consensus document expands the criteria for defining myocardial infarction by adding new ECG criteria and imaging modalities, and also includes patients who present with sudden death. The Israel Heart Society has adopted the new universal definition and recommends its use by clinicians, researchers and epidemiologists. .\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2010\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis.\n \n \n \n \n\n\n \n Whiting, P., F.; Smidt, N.; Sterne, J., A., C.; Harbord, R.; Burton, A.; Burke, M.; Beynon, R.; Ben-Shlomo, Y.; Axford, J.; and Dieppe, P.\n\n\n \n\n\n\n Annals of internal medicine, 152(7): 456-64; W155-66. 4 2010.\n \n\n\n\n
\n\n\n\n \n \n \"SystematicWebsite\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@article{\n title = {Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis.},\n type = {article},\n year = {2010},\n keywords = {anti-CCP,labomailing},\n pages = {456-64; W155-66},\n volume = {152},\n websites = {http://www.ncbi.nlm.nih.gov/books/PMH0029874/},\n month = {4},\n publisher = {Centre for Reviews and Dissemination (UK)},\n day = {6},\n id = {b0c57567-a98e-37c7-8e62-1355571153a9},\n created = {2015-04-14T15:18:37.000Z},\n accessed = {2015-02-04},\n file_attached = {false},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n notes = {Systematische review over de accuraatheid van anti-citrullinated peptide antibodies voor de diagnostiek van RA.},\n private_publication = {false},\n abstract = {BACKGROUND: Early recognition and treatment of rheumatoid arthritis is important to prevent irreversible joint damage. Anti-citrullinated peptide antibodies (ACPA) have been suggested for early diagnosis.\n\nPURPOSE: To compare the accuracy of ACPA and rheumatoid factor in diagnosing rheumatoid arthritis in patients with early symptoms of the disease.\n\nDATA SOURCES: 10 medical databases from inception to September 2009, with no language or publication restrictions, and references of included studies.\n\nSTUDY SELECTION: Two independent reviewers screened searches. Full articles were assessed by one reviewer and checked by a second reviewer to identify studies that reported 2 x 2 data on ACPA for the diagnosis of rheumatoid arthritis (by 1987 American College of Rheumatology criteria).\n\nDATA EXTRACTION: One reviewer abstracted data on patient characteristics, ACPA details, and 2 x 2 data and assessed study quality by using the QUADAS tool. A second reviewer checked extractions.\n\nDATA SYNTHESIS: 151 studies were included, with considerable heterogeneity in sensitivity (range, 12% to 93%) and specificity (range, 63% to 100%). In cohort studies that investigated second-generation anti-cyclic citrullinated peptide antibodies (anti-CCP2) in patients with early rheumatoid arthritis (<2 years), summary sensitivity and specificity were 57% (95% CI, 51% to 63%) and 96% (CI, 93% to 97%), respectively. Case-control and cross-sectional studies and studies of patients with established rheumatoid arthritis all overestimated sensitivity. Anti-CCP2 had greater specificity than rheumatoid factor (96% vs. 86%), with similar sensitivity. Evidence was insufficient to ascertain whether the combination of anti-CCP2 and rheumatoid factor provides additional benefit over anti-CCP2 alone.\n\nLIMITATIONS: Most studies used a diagnostic case-control design, which overestimated sensitivity. Items relating to study quality were rarely reported. Publication bias could not be assessed.\n\nCONCLUSION: Anti-CCP2 should be included in the work-up of patients with early symptoms of rheumatoid arthritis.},\n bibtype = {article},\n author = {Whiting, Penny F and Smidt, Nynke and Sterne, Jonathan A C and Harbord, Roger and Burton, Anya and Burke, Margaret and Beynon, Rebecca and Ben-Shlomo, Yoav and Axford, John and Dieppe, Paul},\n doi = {10.7326/0003-4819-152-7-201004060-00010},\n journal = {Annals of internal medicine},\n number = {7}\n}
\n
\n\n\n
\n BACKGROUND: Early recognition and treatment of rheumatoid arthritis is important to prevent irreversible joint damage. Anti-citrullinated peptide antibodies (ACPA) have been suggested for early diagnosis.\n\nPURPOSE: To compare the accuracy of ACPA and rheumatoid factor in diagnosing rheumatoid arthritis in patients with early symptoms of the disease.\n\nDATA SOURCES: 10 medical databases from inception to September 2009, with no language or publication restrictions, and references of included studies.\n\nSTUDY SELECTION: Two independent reviewers screened searches. Full articles were assessed by one reviewer and checked by a second reviewer to identify studies that reported 2 x 2 data on ACPA for the diagnosis of rheumatoid arthritis (by 1987 American College of Rheumatology criteria).\n\nDATA EXTRACTION: One reviewer abstracted data on patient characteristics, ACPA details, and 2 x 2 data and assessed study quality by using the QUADAS tool. A second reviewer checked extractions.\n\nDATA SYNTHESIS: 151 studies were included, with considerable heterogeneity in sensitivity (range, 12% to 93%) and specificity (range, 63% to 100%). In cohort studies that investigated second-generation anti-cyclic citrullinated peptide antibodies (anti-CCP2) in patients with early rheumatoid arthritis (<2 years), summary sensitivity and specificity were 57% (95% CI, 51% to 63%) and 96% (CI, 93% to 97%), respectively. Case-control and cross-sectional studies and studies of patients with established rheumatoid arthritis all overestimated sensitivity. Anti-CCP2 had greater specificity than rheumatoid factor (96% vs. 86%), with similar sensitivity. Evidence was insufficient to ascertain whether the combination of anti-CCP2 and rheumatoid factor provides additional benefit over anti-CCP2 alone.\n\nLIMITATIONS: Most studies used a diagnostic case-control design, which overestimated sensitivity. Items relating to study quality were rarely reported. Publication bias could not be assessed.\n\nCONCLUSION: Anti-CCP2 should be included in the work-up of patients with early symptoms of rheumatoid arthritis.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative.\n \n \n \n \n\n\n \n Aletaha, D.; Neogi, T.; Silman, A., J.; Funovits, J.; Felson, D., T.; Bingham, C., O.; Birnbaum, N., S.; Burmester, G., R.; Bykerk, V., P.; Cohen, M., D.; Combe, B.; Costenbader, K., H.; Dougados, M.; Emery, P.; Ferraccioli, G.; Hazes, J., M., W.; Hobbs, K.; Huizinga, T., W., J.; Kavanaugh, A.; Kay, J.; Kvien, T., K.; Laing, T.; Mease, P.; Ménard, H., A.; Moreland, L., W.; Naden, R., L.; Pincus, T.; Smolen, J., S.; Stanislawska-Biernat, E.; Symmons, D.; Tak, P., P.; Upchurch, K., S.; Vencovský, J.; Wolfe, F.; and Hawker, G.\n\n\n \n\n\n\n Arthritis and Rheumatism, 62(9): 2569-2581. 2010.\n \n\n\n\n
\n\n\n\n \n \n \"2010Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{\n title = {2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative},\n type = {article},\n year = {2010},\n pages = {2569-2581},\n volume = {62},\n id = {acf3d91a-c42e-3744-95fb-13f79925fa0f},\n created = {2015-08-11T08:43:24.000Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n notes = {De criteria voor de diagnostiek van RA.},\n private_publication = {false},\n abstract = {The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA.},\n bibtype = {article},\n author = {Aletaha, Daniel and Neogi, Tuhina and Silman, Alan J. and Funovits, Julia and Felson, David T. and Bingham, Clifton O. and Birnbaum, Neal S. and Burmester, Gerd R. and Bykerk, Vivian P. and Cohen, Marc D. and Combe, Bernard and Costenbader, Karen H. and Dougados, Maxime and Emery, Paul and Ferraccioli, Gianfranco and Hazes, Johanna M W and Hobbs, Kathryn and Huizinga, Tom W J and Kavanaugh, Arthur and Kay, Jonathan and Kvien, Tore K. and Laing, Timothy and Mease, Philip and Ménard, Henri A. and Moreland, Larry W. and Naden, Raymond L. and Pincus, Theodore and Smolen, Josef S. and Stanislawska-Biernat, Ewa and Symmons, Deborah and Tak, Paul P. and Upchurch, Katherine S. and Vencovský, Jiří and Wolfe, Frederick and Hawker, Gillian},\n doi = {10.1002/art.27584},\n journal = {Arthritis and Rheumatism},\n number = {9}\n}
\n
\n\n\n
\n The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2008\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Onwel na lokale verdoving : is het allergisch ?.\n \n \n \n \n\n\n \n Mulder, W., M., C.\n\n\n \n\n\n\n Nederlands tijdschrift voor allergie, 3(4): 101-105. 2008.\n \n\n\n\n
\n\n\n\n \n \n \"OnwelPaper\n  \n \n \n \"OnwelWebsite\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@article{\n title = {Onwel na lokale verdoving : is het allergisch ?},\n type = {article},\n year = {2008},\n keywords = {allergie,lokale anesthetica},\n pages = {101-105},\n volume = {3},\n websites = {https://www.google.be/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CB8QFjAA&url=http%3A%2F%2Fwww.ariez.nl%2FDownloadFile.lynkx%3Fguid%3D568766a5-0ab2-4349-a5f5-63849d15c4f9&ei=cu1RVbCRJIT_UOOngeAG&usg=AFQjCNEalUOAU165I1JR8dnvqP5Tf7OWvA&sig},\n id = {21a86094-3d94-3aae-a493-d22f6d609ac6},\n created = {2015-05-12T12:24:41.000Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n private_publication = {false},\n abstract = {Wanneer patiënten klachten ervaren na het ondergaan van een lokale verdoving, is er vaak de angst allergisch te zijn. Echter, de meeste klachten die binnen 12 uur na een behandeling optreden zijn het gevolg van lokaal anaesthe- ticum dat in te hoge concentratie in de circu- latie terecht komt. Niet-allergische klachten komen vaker voor bij patiënten met angst, cardiovasculaire aandoeningen, mannen en na langdurige ingrepen. De kans op herhaling van niet-allergische klachten is gering wanneer de lokale anaesthesie adequaat wordt uitgevoerd. Een allergische reactie is zeldzaam en kan wor- den veroorzaakt door lokaal anaestheticum, toevoegingen zoals adrenaline/epinefrine en conserveermiddelen, maar ook door andere gebruikte geneesmiddelen zoals NSAID en anti- biotica. Wanneer na zorgvuldige anamnese een allergische reactie niet kan worden uitgesloten, is allergologisch onderzoek nodig. (Ned},\n bibtype = {article},\n author = {Mulder, W M C},\n journal = {Nederlands tijdschrift voor allergie},\n number = {4}\n}
\n
\n\n\n
\n Wanneer patiënten klachten ervaren na het ondergaan van een lokale verdoving, is er vaak de angst allergisch te zijn. Echter, de meeste klachten die binnen 12 uur na een behandeling optreden zijn het gevolg van lokaal anaesthe- ticum dat in te hoge concentratie in de circu- latie terecht komt. Niet-allergische klachten komen vaker voor bij patiënten met angst, cardiovasculaire aandoeningen, mannen en na langdurige ingrepen. De kans op herhaling van niet-allergische klachten is gering wanneer de lokale anaesthesie adequaat wordt uitgevoerd. Een allergische reactie is zeldzaam en kan wor- den veroorzaakt door lokaal anaestheticum, toevoegingen zoals adrenaline/epinefrine en conserveermiddelen, maar ook door andere gebruikte geneesmiddelen zoals NSAID en anti- biotica. Wanneer na zorgvuldige anamnese een allergische reactie niet kan worden uitgesloten, is allergologisch onderzoek nodig. (Ned\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2006\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).\n \n \n \n \n\n\n \n Zhang, W.; Doherty, M.; Bardin, T.; Pascual, E.; Barskova, V.; Conaghan, P.; Gerster, J.; Jacobs, J.; Leeb, B.; Lioté, F.; McCarthy, G.; Netter, P.; Nuki, G.; Perez-Ruiz, F.; Pignone, A.; Pimentão, J.; Punzi, L.; Roddy, E.; Uhlig, T.; Zimmermann-Gòrska, I.; and EULAR Standing Committee for International Clinical Studies Including Therapeutics\n\n\n \n\n\n\n Annals of the rheumatic diseases, 65(10): 1312-24. 10 2006.\n \n\n\n\n
\n\n\n\n \n \n \"EULARPaper\n  \n \n \n \"EULARWebsite\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@article{\n title = {EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).},\n type = {article},\n year = {2006},\n pages = {1312-24},\n volume = {65},\n websites = {http://ard.bmj.com/cgi/doi/10.1136/ard.2006.055269,http://www.ncbi.nlm.nih.gov/pubmed/16707532,http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1798308},\n month = {10},\n day = {28},\n id = {0d1e722e-a973-3f8b-afb6-fbe43443b7ce},\n created = {2016-01-26T13:23:11.000Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n private_publication = {false},\n abstract = {OBJECTIVE To develop evidence based recommendations for the management of gout. METHODS The multidisciplinary guideline development group comprised 19 rheumatologists and one evidence based medicine expert representing 13 European countries. Key propositions on management were generated using a Delphi consensus approach. Research evidence was searched systematically for each proposition. Where possible, effect size (ES), number needed to treat, relative risk, odds ratio, and incremental cost-effectiveness ratio were calculated. The quality of evidence was categorised according to the level of evidence. The strength of recommendation (SOR) was assessed using the EULAR visual analogue and ordinal scales. RESULTS 12 key propositions were generated after three Delphi rounds. Propositions included both non-pharmacological and pharmacological treatments and addressed symptomatic control of acute gout, urate lowering therapy (ULT), and prophylaxis of acute attacks. The importance of patient education, modification of adverse lifestyle (weight loss if obese; reduced alcohol consumption; low animal purine diet) and treatment of associated comorbidity and risk factors were emphasised. Recommended drugs for acute attacks were oral non-steroidal anti-inflammatory drugs (NSAIDs), oral colchicine (ES = 0.87 (95% confidence interval, 0.25 to 1.50)), or joint aspiration and injection of corticosteroid. ULT is indicated in patients with recurrent acute attacks, arthropathy, tophi, or radiographic changes of gout. Allopurinol was confirmed as effective long term ULT (ES = 1.39 (0.78 to 2.01)). If allopurinol toxicity occurs, options include other xanthine oxidase inhibitors, allopurinol desensitisation, or a uricosuric. The uricosuric benzbromarone is more effective than allopurinol (ES = 1.50 (0.76 to 2.24)) and can be used in patients with mild to moderate renal insufficiency but may be hepatotoxic. When gout is associated with the use of diuretics, the diuretic should be stopped if possible. For prophylaxis against acute attacks, either colchicine 0.5-1 mg daily or an NSAID (with gastroprotection if indicated) are recommended. CONCLUSIONS 12 key recommendations for management of gout were developed, using a combination of research based evidence and expert consensus. The evidence was evaluated and the SOR provided for each proposition.},\n bibtype = {article},\n author = {Zhang, W and Doherty, M and Bardin, T and Pascual, E and Barskova, V and Conaghan, P and Gerster, J and Jacobs, J and Leeb, B and Lioté, F and McCarthy, G and Netter, P and Nuki, G and Perez-Ruiz, F and Pignone, A and Pimentão, J and Punzi, L and Roddy, E and Uhlig, T and Zimmermann-Gòrska, I and EULAR Standing Committee for International Clinical Studies Including Therapeutics, undefined},\n doi = {10.1136/ard.2006.055269},\n journal = {Annals of the rheumatic diseases},\n number = {10},\n keywords = {jicht,urinezuur}\n}
\n
\n\n\n
\n OBJECTIVE To develop evidence based recommendations for the management of gout. METHODS The multidisciplinary guideline development group comprised 19 rheumatologists and one evidence based medicine expert representing 13 European countries. Key propositions on management were generated using a Delphi consensus approach. Research evidence was searched systematically for each proposition. Where possible, effect size (ES), number needed to treat, relative risk, odds ratio, and incremental cost-effectiveness ratio were calculated. The quality of evidence was categorised according to the level of evidence. The strength of recommendation (SOR) was assessed using the EULAR visual analogue and ordinal scales. RESULTS 12 key propositions were generated after three Delphi rounds. Propositions included both non-pharmacological and pharmacological treatments and addressed symptomatic control of acute gout, urate lowering therapy (ULT), and prophylaxis of acute attacks. The importance of patient education, modification of adverse lifestyle (weight loss if obese; reduced alcohol consumption; low animal purine diet) and treatment of associated comorbidity and risk factors were emphasised. Recommended drugs for acute attacks were oral non-steroidal anti-inflammatory drugs (NSAIDs), oral colchicine (ES = 0.87 (95% confidence interval, 0.25 to 1.50)), or joint aspiration and injection of corticosteroid. ULT is indicated in patients with recurrent acute attacks, arthropathy, tophi, or radiographic changes of gout. Allopurinol was confirmed as effective long term ULT (ES = 1.39 (0.78 to 2.01)). If allopurinol toxicity occurs, options include other xanthine oxidase inhibitors, allopurinol desensitisation, or a uricosuric. The uricosuric benzbromarone is more effective than allopurinol (ES = 1.50 (0.76 to 2.24)) and can be used in patients with mild to moderate renal insufficiency but may be hepatotoxic. When gout is associated with the use of diuretics, the diuretic should be stopped if possible. For prophylaxis against acute attacks, either colchicine 0.5-1 mg daily or an NSAID (with gastroprotection if indicated) are recommended. CONCLUSIONS 12 key recommendations for management of gout were developed, using a combination of research based evidence and expert consensus. The evidence was evaluated and the SOR provided for each proposition.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2001\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Monoklonale gammopathie (paraproteïnemie).\n \n \n \n \n\n\n \n Kwaliteitsinstituut voor de gezondheidszorg CBO\n\n\n \n\n\n\n Van Zuiden Communications B.V., 2001.\n \n\n\n\n
\n\n\n\n \n \n \"MonoklonalePaper\n  \n \n \n \"MonoklonaleWebsite\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@book{\n title = {Monoklonale gammopathie (paraproteïnemie)},\n type = {book},\n year = {2001},\n keywords = {elektroforese,immunofixatie},\n pages = {1-78},\n websites = {www.cbo.nl,www.diliguide.nl,http://www.diliguide.nl/document/3458},\n publisher = {Van Zuiden Communications B.V.},\n city = {Utrecht},\n id = {46e8995b-6f29-3752-af73-f205afe04dcb},\n created = {2015-04-20T13:27:16.000Z},\n file_attached = {true},\n profile_id = {941c2fd4-a583-308f-aea6-f6aaaa4aba4e},\n group_id = {11b7b7d1-f1e4-3f77-b9b5-edc01e5cb9b5},\n last_modified = {2017-03-14T15:14:50.027Z},\n read = {true},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n notes = {De richtlijn adviseert om een klinische vraagstelling op de aanvraagformulieren te zetten in de plaats van technieken zoals elektroforese of immunofixatie.<br/><br/>Geef bij antwoord van de immunofixatie info over het type, de plaats en de concentratie van het M-proteïne.<br/><br/>Urine niet invriezen want dit kan leiden tot een aanzienlijk verlies van lichte ketens.<br/><br/>Ze voorzien ook een aparte aanvraag voor het zoeken naar M-proteïnen, waarbij bij een negatieve elektroforese, toch een IF wordt uitgevoerd.},\n private_publication = {false},\n bibtype = {book},\n author = {Kwaliteitsinstituut voor de gezondheidszorg CBO, undefined}\n}
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);